Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

LigoCyte

- PMLiVE

Takeda hands back rights to two Amgen drugs

Returns pain and ovarian cancer candidates but will continue with collaboration

- PMLiVE

CDC says no to AZ’s intranasal flu vaccine FluMist

US government data reports “poor” efficacy for the injected vaccine alternative

- PMLiVE

Takeda starts trial of norovirus vaccine

If approved the drug is anticipated to surpass sales of GSK’s Rotarix vaccine

- PMLiVE

Circassia slumps as cat allergy vaccine fails late-stage trial

Has suspended several trials after an “unprecedented” placebo effect derailed leading drug candidate

- PMLiVE

FDA approves first cholera vaccine in US

PaxVax’s oral vaccine Vaxchora will be launched by September

- PMLiVE

Takeda forms new women’s health and cancer company

Recruits former Medivation CMO Lynn Seely to lead Myovant Sciences

Takeda appoints chief financial officer and corporate officer

James Kehoe takes on both roles from 15 June

UK Life Sciences Strategy - one year on

Astellas, Daiichi Sankyo and Takeda to study biomarkers

Collaboration aims to establish comprehensive database to accelerate drug development

- PMLiVE

Drone delivery of vaccine supplies planned in Rwanda

Gavi, UPS and Zipline hope new network will be a test-case for other countries

- PMLiVE

Teva and Takeda appoint head of Japanese generics venture

Hiroshi Matsumori will lead partnership of Teva’s generics portfolio and Takeda brands

- PMLiVE

Genital herpes vaccine candidate promising in phase II

Genocea Biosciences’ GEN-003 found to reduce recurrence and transmission of the virus

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links